资讯

Investor's Business Daily on MSN57 分钟
Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It
Bristol Myers Squibb stock skidded late Monday, tugging Cytokinetics lower, after Bristol's drug, Camzyos, failed in a heart disease study.